Redeye: Alzinova - What the aducanumab failure means for the prospects of ALZ-101

Report this content

A couple of weeks ago, Biogen/Eisai announced the discontinuation of aducanumab programs, including the phase III trials, ENGAGE and EMERGE. In this report, we provide a thorough analysis of what the latest news regarding aducanumab means for Alzinova’s lead candidate, ALZ-101. We factor in a higher development risk post-aducanumab news, which has led to updated valuations.

Read more and download the Research Update:

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.